SAN CARLOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) presented five-year data from its Phase 2 C-144-01 trial of Amtagvi (lifileucel) during the 2025 ASCO Annual Meeting. A medical staff in white coats ...

SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- Biotechnology firm Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is facing a securities class action lawsuit in the Northern District of California ...

Now this is a fine way for a stock to greet the new year. On the back of a glowing analyst recommendation, Iovance Biotherapeutics's (NASDAQ: IOVA) shares closed Thursday more than 5% higher in price.

Results from the Phase II C-144-01 trial show that Iovance Biotherapeutics’ Amtagvi (lifileucel) demonstrated deep and durable responses in patients with advanced melanoma previously treated with anti ...

On Tuesday, Citizens JMP analysts reiterated a Market Perform rating on Iovance Biotherapeutics stock (NASDAQ: NASDAQ:IOVA), which has declined nearly 80% over the past year. According to ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) presented five-year data from its Phase 2 C-144-01 trial of Amtagvi (lifileucel) during the 2025 ASCO Annual Meeting. A medical staff in white coats ...

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, May 25, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance ...

(MENAFN- EIN Presswire) NEW YORK, May 25, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics ...

Instead of making the “o” in Shutterstock look like a viewfinder, now it has “ripples” coming off the top and bottom to ...

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ...

Iovance is a commercial-stage biopharmaceutical company focused on the development of treatments for melanoma and other solid tumor cancers. The Company commercially launched its key melanoma ...